The Epilepsy Foundation supports a series of grants and fellowships to advance the understanding of epilepsy that will lead to better treatment, more effective prevention, and ultimately to a cure. Funding is available to researchers at all professional levels including students, junior investigators and established investigators.

PATENT AND COPYRIGHT POLICY

Please note that the Epilepsy Foundation Patent and Copyright Policy applies primarily to awards offered to academic institutions and is open to clarification as needed. Commercial companies that are offered funding to support their research will have the opportunity to negotiate a suitable agreement with the Foundation regarding intellectual property rights as needed.

The Epilepsy Foundation has two funding cycles per year.  Not all programs are offered in each cycle. Only those listed under “Current Funding Opportunities” below are available now.

General Timeline:  Please check back in January and June for exact due dates for each cycle.

Spring

  • Grant opportunities announced: January
  • Letters of Intent (LOIs) due: late February - early March
  • LOI review: early – mid March
  • Full applications due:  May
  • Application Review: May-June
  • Funding Decision: late June

Fall

  • Grant opportunities announced: June
  • LOIs due: early August
  • LOI review: mid-August
  • Full applications due: end of September
  • Application Review: October-November
  • Funding Decision: late November

Current Funding Opportunities - Fall 2017

For researchers intending to apply for funding, please download the information and instructions for each program listed below.

Anticipated Timeline - NTCG and SEAL

  • July 21, 2017: LOI's due
  • Week of August 14, 2017: LOI outcomes emailed to applicants
  • September 25, 2017: Applications due
  • Early December 2017: Peer Review Committee Meetings
  • Mid December 2017: Outcome notifications send to applicants
  • Beginning January 2018: Award Period

Anticipated Timeline - TRICE

  • September 25, 2017: Applications due
  • Late October - Early November 2017: Peer Review Committee Meeting
  • Early December 2017: Funding decision/applicant notification
  • Beginning January 1, 2018: Award Period

 



New Therapy Commercialization Grant

Letters of Intent due: July 21, 2017 - apply via proposalCENTRAL

The Epilepsy Foundation - New Therapy Commercialization Grants Program supports the development of more effective therapies by serving as a catalyst for moving innovative therapies from the laboratory to the patient. Investigators must hold a relevant advanced degree (M.D., and/or Ph.D.), and have completed all research training. This call for proposals is open to investigators at corporations as well as the academic/university arena.

For the New Therapy–Commercialization Grants, the Epilepsy Foundation encourages 1:1 matching grants to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. These matching funds seek to leverage other resources, and accelerate the pace of therapeutic advances. Preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third party source. For the New Therapy Commercialization Grants, applicants must demonstrate background work beyond the basic science discovery stage.

Epilepsy Innovation Seal of Excellence

Letters of Intent due: July 21, 2017 - apply via proposalCENTRAL

The Epilepsy Innovation Seal of Excellence award is similar to the Epilepsy Foundation - New Therapy Commercialization Grants (NTCG) Program above, designed to accelerate the advancement of research from the laboratory to the patient. SEALs are provided to academic and commercial groups worldwide. The program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. Drug development may be stimulated at the early phases leading to an IND.

The Epilepsy Innovation Seal of Excellence award is not primarily a grant program. The program provides a competitive, in-depth review by the Scientific and Business Advisory Boards and an actual SEAL that may be used by the awardee to generate interest in the project.  The applicants will typically have a research budget of between $1 and $5M for the overall project--amounts that currently exceed the resources of the Epilepsy Foundation. The Epilepsy Foundation will assist the awardees in finding funds for the selected projects.